facebook twitter youtube

News archive

Recent news


The largest haematology meeting in the calendar year, the American Society of Hematology (ASH) Annual Meeting, was held virtually from 5 to 8 December 2020. Continue reading


A new study suggests the monoclonal antibody daratumumab has similar benefits when delivered via subcutaneous injection as it does when delivered intravenously to patients which myeloma persists or recurs after first-line treatments. Patients given subcutaneous daratumumab along with the immunomodulator pomalidomide and the anti-inflammatory steroid dexamethasone were 37% less likely to die or have their disease worsen compared to patients who received pomalidomide and dexamethasone alone in the phase III trial. Continue reading